Stryker Launches Mako RPS, But Valuation Remains Stretched

What happened

Stryker launched Mako RPS, a handheld robotic system for total knee replacement, expanding its robotic surgery portfolio to a broader range of providers. The device aims to increase access to robotic-assisted procedures, potentially driving higher implant volumes and strengthening Stryker's competitive position. However, the stock trades at roughly 46 times trailing earnings and 30 times EV/EBITDA, a significant premium to a discounted cash flow estimate of about $124 per share. Near-term headwinds include an estimated $175–200 million tariff drag in 2025, integration risks from recent acquisitions like Inari Medical, and intensifying competition from Zimmer Biomet's ROSA and Johnson & Johnson's Velys platforms. While Mako RPS supports Stryker's innovation narrative, the elevated multiple leaves little margin for error, reinforcing the view that the stock is fully priced.

Implication

The launch of Mako RPS enhances Stryker's robotic surgery capabilities and could support mid-single-digit growth in knee procedures over the medium term. However, with the stock trading at a substantial premium to intrinsic value (~46x P/E vs. DCF of $124), the market already prices in significant future growth. Any disappointment in robot attach rates, tariff impacts, or competitive dynamics could trigger multiple compression. Investors should monitor Mako adoption metrics and margin trends before adding positions, as the risk-reward remains unfavorable at current levels.

Thesis delta

The Mako RPS launch modestly strengthens Stryker's competitive moat in robotics but does not alter the fundamental valuation concern. The thesis remains skewed toward trimming or selling into strength unless the stock de-rates materially to levels closer to intrinsic value.